112 related articles for article (PubMed ID: 26444701)
1. Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression.
Ghabrash MF; Comai S; Tabaka J; Saint-Laurent M; Booij L; Gobbi G
World J Biol Psychiatry; 2016; 17(2):165-70. PubMed ID: 26444701
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression.
Gobbi G; Ghabrash MF; Nuñez N; Tabaka J; Di Sante J; Saint-Laurent M; Vida S; Kolivakis T; Low N; Cervantes P; Booij L; Comai S
Int Clin Psychopharmacol; 2018 Jan; 33(1):34-43. PubMed ID: 28906325
[TBL] [Abstract][Full Text] [Related]
3. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
4. Evidence to Support Montgomery-Asberg Depression Rating Scale Administration Every 24 Hours to Assess Rapid Onset of Treatment Response.
Johnson KM; Devine JM; Ho KF; Howard KA; Saretsky TL; Jamieson CA
J Clin Psychiatry; 2016 Dec; 77(12):1681-1686. PubMed ID: 28086004
[TBL] [Abstract][Full Text] [Related]
5. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
8. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
[TBL] [Abstract][Full Text] [Related]
9. Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant Depression.
Moderie C; Nuñez N; Fielding A; Comai S; Gobbi G
Int J Neuropsychopharmacol; 2022 Jun; 25(6):479-488. PubMed ID: 35167671
[TBL] [Abstract][Full Text] [Related]
10. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
11. Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
Möller HJ; Demyttenaere K; Olausson B; Szamosi J; Wilson E; Hosford D; Dunbar G; Tummala R; Eriksson H
World J Biol Psychiatry; 2015 Oct; 16(7):483-501. PubMed ID: 25602163
[TBL] [Abstract][Full Text] [Related]
12. Intravenous arketamine for treatment-resistant depression: open-label pilot study.
Leal GC; Bandeira ID; Correia-Melo FS; Telles M; Mello RP; Vieira F; Lima CS; Jesus-Nunes AP; Guerreiro-Costa LNF; Marback RF; Caliman-Fontes AT; Marques BLS; Bezerra MLO; Dias-Neto AL; Silva SS; Sampaio AS; Sanacora G; Turecki G; Loo C; Lacerda ALT; Quarantini LC
Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):577-582. PubMed ID: 32078034
[TBL] [Abstract][Full Text] [Related]
13. Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.
Murrough JW; Wade E; Sayed S; Ahle G; Kiraly DD; Welch A; Collins KA; Soleimani L; Iosifescu DV; Charney DS
J Affect Disord; 2017 Aug; 218():277-283. PubMed ID: 28478356
[TBL] [Abstract][Full Text] [Related]
14. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P
CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate.
Langosch JM; Drieling T; Biedermann NC; Born C; Sasse J; Bauer H; Walden J; Bauer M; Grunze H
J Clin Psychopharmacol; 2008 Oct; 28(5):555-60. PubMed ID: 18794653
[TBL] [Abstract][Full Text] [Related]
17. Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression.
Zimmerman M; Posternak MA; Chelminski I
J Psychiatr Res; 2004; 38(6):577-82. PubMed ID: 15458853
[TBL] [Abstract][Full Text] [Related]
18. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
Bauer M; Thase ME; Liu S; Earley W; Eriksson H
J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
[TBL] [Abstract][Full Text] [Related]
19. Venlafaxine for treatment-resistant unipolar depression.
Nierenberg AA; Feighner JP; Rudolph R; Cole JO; Sullivan J
J Clin Psychopharmacol; 1994 Dec; 14(6):419-23. PubMed ID: 7884023
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded, prospective study.
Han C; Wang SM; Kwak KP; Won WY; Lee H; Chang CM; Tang TC; Pae CU
J Psychiatr Res; 2015; 66-67():84-94. PubMed ID: 26013203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
